Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics

Jan 31, 2024•over 1 year ago

Amount Raised

$30 Million

LehiBiotechnology

Investors

Todd Pedersen

Description

Halia Therapeutics announced the completion of a $30 million Series C financing led by Todd Pedersen, with continued participation from existing investors. The funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia's first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic.

Company Information

Company

Halia Therapeutics

Location

3900 N. Traverse Mountain Blvd

Lehi, Utah, United States

About

Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics

Investors

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Related People

Company Information